Meis3 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that would inhibit the PI3K/Akt signaling pathway, leading to a decrease in cell survival and proliferation signals. Since Meis3 is known to be involved in regulating developmental processes and survival, inhibition of the PI3K/Akt pathway would result in decreased Meis3 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting this pathway, PD98059 would reduce the ERK-mediated transcriptional activation of genes involved in cell cycle progression, potentially leading to a decrease in Meis3 protein activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that would lead to suppression of the MAPK/ERK pathway, thereby inhibiting the downstream signaling that could affect Meis3's role in transcriptional regulation of developmental genes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta type I receptor ALK5, which is involved in the TGF-beta signaling pathway. Inhibition of this pathway would lead to reduced cellular differentiation signals that Meis3 is known to mediate. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth and proliferation. By inhibiting mTOR, Rapamycin would reduce the cellular growth signals that are necessary for Meis3 function in cellular growth and development. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor like LY294002, leading to inhibition of the PI3K/Akt pathway which would diminish the survival and proliferation signals that Meis3 is associated with in its regulatory functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathway. Inhibition of JNK would lead to reduced stress response signals that could decrease Meis3 activity as it is implicated in cellular response to environmental stress. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases, which are involved in multiple signaling pathways, including those regulating actin cytoskeleton. Inhibition of these pathways would lead to reduced Meis3 activity in processes such as cell migration and adhesion. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor, which would inhibit the RAF/MEK/ERK signaling cascade, leading to decreased cell division signals. Meis3-associated activities in cell proliferation would be diminished as a result. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib targets ABL, c-KIT, and PDGFR tyrosine kinases, leading to inhibition of signaling pathways that regulate cell growth and survival, which would result in decreased activity of Meis3 protein in these pathways. | ||||||